Cilostazol Effectively Reduces the Decrease of Flow Volume in a Thrombotic Anastomosis Model in a Rat
- 김상현; 장혁원; 최태현; 김준형; 손대구; 한기환; 이소영
- Alternative Author(s)
- Kim, Sang Hyon; Chang, Hyuk Won; Choi, Tae Hyun; Kim, Jun Hyung; Son, Dae Gu; Han, Ki Hwan; Lee, So Young
- Publication Year
- The purpose of this study was to investigate the efficacy of
cilostazol for prevention of thrombosis in microsurgical anastomosis. We
used not only a patency test, but also ultrasonography to evaluate the blood
flow volume (FV) more accurately and objectivity. In addition, we evaluated
the accuracy and sensitivity of the patency test.
Thrombogenic anastomoses were performed on rat external iliac arteries.
Forty-six rats were randomly allocated into the following 5 experimental
groups: negative control, without any surgery and medication; control,
received distilled water orally; group A, received aspirin orally; group B,
received cilostazol orally; and group C, received aspirin and cilostazol orally
3 hours before a thrombogenic artery anastomosis. The artery was evaluated
by FV using ultrasonography and a patency test 10, 30, and 120 minutes after
The FV in group C was significantly larger than the control group 30
minutes after clamp removal. The FVs in groups A, B, and C were
significantly larger than the control group 120 minutes after clamp removal.
The FV decreased in all groups with time. The patency rate between the
control group and group C 120 minutes after clamp removal was significantly
different. There were 8 false negatives in a total of 114 patency tests. The
total accuracy and sensitivity of the patency test were 93.0% and 92.7%,
Cilostazol plus aspirin therapy is recommended for reducing thrombosis
and increasing FV without increasing the risk of bleeding during microsurgery.
The patency test cannot evaluate the state of the anastomotic vessels
accurately and objectively.
Key Words: cilostazol, thrombotic anastomosis model, ultrasonography
- Authorize & License
- Files in This Item:
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.